CBPO China Bioligic Products Holdings Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 001-34566

 

 

China Biologic Products, Inc.*

(Exact name of registrant as specified in its charter)

 

 

18th Floor, Jialong International Building
19 Chaoyang Park Road
Chaoyang District, Beijing
People’s Republic of China  

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, $0.0001 par value per share

Preferred Share Purchase Rights

(Title of each class of securities covered by this Form)

 

None*

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	¨
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	¨
Rule 15d-6	¨

 

Approximate number of holders of record as of the certification or notice date: 0 *

 

 

Explanatory Note

 

* Effective July 21, 2017, China Biologic Products, Inc., a Delaware corporation (the “Predecessor”), completed the redomicile merger (the “Redomicile Merger”) to reorganize itself as a Cayman Islands company, as contemplated by the agreement and plan of merger dated as of April 28, 2017 (the “Merger Agreement”) by and among the Predecessor and China Biologic Products Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Predecessor (the “Successor”). Pursuant to the Merger Agreement, each issued and outstanding share of the common stock of the Predecessor was converted into the right to receive one ordinary share of the Successor. The Redomicile Merger constitutes a succession for purpose of Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Form 15 relates solely to the reporting obligations of the Predecessor under the Exchange Act, and does not affect the reporting obligations of the Successor under the Exchange Act.

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, China Biologic Products Holdings, Inc., as successor to China Biologic Products, Inc., has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

Date:	July 21, 2017	By:	/s/ David (Xiaoying) Gao
		Name:	David (Xiaoying) Gao
		Title:	Chief Executive Officer